Aptamer Group PLC
20 August 2026
20 August 2026
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Appointment of Joint Corporate Broker
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, is pleased to announce the appointment of Cavendish Capital Markets Limited ("Cavendish") as Joint Corporate Broker to the Company with immediate effect.
Cavendish will work alongside Turner Pope Investments (TPI) Limited, which will continue to act as Joint Corporate Broker.
As Aptamer continues to advance its therapeutic programmes, the appointment is intended to broaden research coverage and institutional engagement, drawing on Cavendish's specialist healthcare expertise and established relationships within the life sciences sector.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Dillon Wall |
+44 (0) 20 3368 3550 |
|
Cavendish Capital Markets Limited - Joint Broker Geoff Nash / Seamus Fricker / Joe Smith |
+44 (0) 20 7220 0500 |
|
Turner Pope Investments (TPI) Limited - Joint Broker Andrew Thacker / Guy McDougall |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.
The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.
Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.
The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with upcoming in vivo studies expected to support future partnering and licensing opportunities.
Founded in 2008 and headquartered in York, UK, Aptamer works with many of the world's leading pharmaceutical companies, combining platform expertise, proprietary data and therapeutic innovation to create shareholder value.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.